An Early Phase 1 interventional study of GLP-1 Receptor Agonists in Lymphedema, sponsored by Advanced Reconstructive Surgery Alliance. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-10.
Sponsored by Advanced Reconstructive Surgery Alliance · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 168 studies in Lymphedema with a site in United States — 37 open to participants now, 45 under way, 1 of them phase 3. Lymphedema · United States.
Among the 168 studies in Lymphedema with a site in United States, this one is the 27th largest by planned enrollment of the 122 interventional ones that give a count, is one of 7 that started in 2025, is one of 8 in phase 1, reaches primary completion later than 17 of the 44 other live ones, and was the 162nd registered.
529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.
Browse Lymphedema studies →37 of the 168 studies in Lymphedema with a site in United States are open now. Recruiting first, the newest first:
University of Pittsburgh · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Women only
Tactile Medical · Sites in United States
Ages 18+
University Hospital, Basel, Switzerland · Sites in United States, Austria, Canada and 8 more countries
Ages 18+
University of South Florida · Sites in United States
Ages 18–75 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 84 Lymphedema studies recruiting now, 46 (55%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
168 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 22 · Phase 3 4 · Phase 4 4
First in 2001; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is above the median of 52 across 369 interventional studies indexed under Lymphedema.
Median enrollment 50 across the 122 interventional studies, 148 across the 44 observational. Of the 114 that completed or were terminated, 39 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 168 have an industry lead sponsor. The 10 most frequent:
Advanced Reconstructive Surgery Alliance is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Advanced Reconstructive Surgery Alliance has 1 study filed under Lymphedema — fewer than ten, so there is no comparison to draw.
12 of the studies in Lymphedema with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05825157Stanford UniversityEvaluation of Combination Therapy for Upper Extremity Lymphedema | 2027-01-01 |
| NCT02743858Memorial Sloan Kettering Cancer CenterLymphedema Surveillance Study | 2027-04 |
| NCT07012642Advanced Reconstructive Surgery AllianceEfficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema | 2027-04-09 |
| NCT05366699Stanford UniversityLYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy | 2027-06-01 |
| NCT05182229Abramson Cancer Center at Penn MedicineComparing Two Ways to Manage Head and Neck Lymphedema | 2027-06-30 |
Add all 12 to your calendar (.ics) → With an account.
Among the 168 studies in Lymphedema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Lymphedema affects millions and currently lacks effective drug treatments, relying mainly on compression therapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential in managing obesity and diabetes, which can worsen lymphedema. Although anecdotal evidence suggests benefits of GLP-1 RAs for lymphedema patients, rigorous prospective studies are lacking. This study aims to evaluate the effectiveness of GLP-1 RAs in improving quality of life and clinical outcomes in lymphedema patients, thereby addressing a critical gap in literature and potentially offering a new treatment option.
Research Protocol: GLP-1Ras - Investigator-Initiated Study
Principal Investigator: Joseph Dayan, MD, MBA
Title: Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema
Background and Rationale
Introduction: Lymphedema is an incurable and relentless progressive disease marked by swelling of the upper or lower limb requiring life-long compression. Patients have a high risk of cellulitis and deteriorating quality of life. Lymphedema is a major public health problem with an estimated incidence in the United States of 5 million. There is no cure and no drug to treat this disease.
Literature Review: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now ubiquitous in the United States given their effectiveness in treating obesity and diabetes. Elevated BMI and insulin resistance have been widely reported to worsen lymphedema. Consequently, GLP-1 RAs may have a positive effect on lymphedema. Anecdotally we have observed patients with chronic lymphedema dramatically improve after taking GLP-1 receptor agonists but there is currently no prospective data available.
Rationale: Lymphedema affects millions and currently lacks effective drug treatments, relying mainly on compression therapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential in managing obesity and diabetes, which can worsen lymphedema. Although anecdotal evidence suggests benefits of GLP-1 RAs for lymphedema patients, rigorous prospective studies are lacking. This study aims to evaluate the effectiveness of GLP-1 RAs in improving quality of life and clinical outcomes in lymphedema patients, thereby addressing a critical gap in literature and potentially offering a new treatment option.
Objectives
Primary Objective: To evaluate the quality-of-life improvements following GLP-1 RA treatment, utilizing the Lymphedema Life Impact Scale (LLIS) as a measurement tool.
Secondary Objectives: To evaluate the efficacy of GLP-1 RAs in reducing limb volume, bioimpedance, compression use, and incidence of cellulitis.
Hypotheses
GLP-1 receptor agonists will improve quality of life and reduce limb volume in lymphedema patients.
Study Design
Type of Study: Prospective, Single arm study, off-label use of GLP-1 receptor agonists to treat upper or lower extremity lymphedema.
Duration: 24 Months
Study Setting: Conduct at an outpatient lymphedema clinic
Population: Adults with Upper and lower extremity Lymphedema, (ISL) stages II and II
Sample Size: 110 participants
Follow-up Visits: Baseline, 3 months, and 6 months post-treatment visit
Participants
Eligibility Criteria
Inclusion Criteria:
Adults 18 years or older with unilateral upper or lower extremity lymphedema Limb volume > 5% BMI => 23 Oncology clearance if there is a cancer history
Exclusion Criteria:
Moderate to severe venous insufficiency Actively using GLP-1 RAs Known intolerance or adverse effect to GLP-1 RAs Medical history or morbidity where GLP-1 RAs are contraindicated as per patient's primary care provider such as MEN syndrome or history of thyroid cancer
Methods
Data Collection:
Lymphedema Life Impact Scale score (validated patient-reported outcome metric) Limb volume Bioimpedance BMI Compression use Incidence of cellulitis
Interventions: GLP-1 RA treatment will be administered by the patient's primary provider for 6 months.
Outcome Measures
Primary Outcome:
Patient reported quality of life outcome (Lymphedema Life Impact Scale)
Secondary Outcomes:
Limb volume Bioimpedance BMI Incidence of cellulitis Compression use
Data Analysis Plan
Statistical Methods:
Utilize appropriate statistical tests, including a t-test with an effect size of 0.15 and a power of 0.95.
To adequately power this study, 74 participants are needed to complete a 6-month course of GLP-1 RA treatment and follow-up. Assuming a dropout rate of 30%, we plan to enroll 110 patients to meet this goal.
Software:
IBM SPSS for data analysis.
Handling Missing Data:
To address missing data, all instances will be documented, and efforts will be made to recover missing information. Multiple imputation techniques will be used to estimate missing values for continuous variables, such as limb volume and LLIS scores. Sensitivity analyses will be conducted to evaluate the impact of missing data on study outcomes, ensuring robustness and transparency in the study's findings.
Ethical Considerations
Informed Consent:
Participants will provide informed consent, understanding the study's scope and procedures.
Confidentiality:
Participant data will be kept confidential, adhering to ethical standards.
Approval:
Ethical approval will be obtained from a relevant ethics committee or institutional review board (IRB).
Study Timeline Estimated Start Date: April 9, 2025
Estimated Completion Date: April 9, 2027
Recruitment:
Recruit patients from internal lymphedema population Clinicaltrials.gov Patient referrals from other providers and social media
Budget and Funding
Budget:
No anticipated study costs. The study participation is voluntary
Funding Sources:
The project is currently not funded
Potential Risks and Benefits
Risks, benefits, and alternatives to GLP-1 RA treatment will be discussed with the patient in addition to the patient reviewing this consideration with their provider.
The most common adverse event from GLP-1 treatment is gastrointestinal intolerance such as nausea or vomiting (5% incidence).
Adverse events:
The site will begin to report AE/SAE after the patient signs the informed consent.
All serious adverse events (SAEs) will be documented and reported to the Institutional Review Board (IRB) within 24 hours of the patient site becoming aware.
Participant Discontinuation/ Withdrawal from the study:
Participants have the right to withdraw from the study at any time upon their request.
Dissemination Plan:
The results of the study will be submitted as a research manuscript for publication in a peer-reviewed journal either the New England Journal of Medicine or the Journal of the American Medical Association.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults 18 years or older with unilateral upper or lower extremity lymphedema Limb volume > 5% => 23 Oncology clearance if there is a cancer history
Exclusion Criteria:
Moderate to severe venous insufficiency Actively using GLP-1 RAs Known intolerance or adverse effect to GLP-1 RAs Medical history or morbidity where GLP-1 RAs are as per patient's primary care provider such as MEN syndrome or history of thyroid cancer.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will received GLP-1 RAs for 6 months to study the effects on lymphedema.
Drug: GLP-1 Receptor Agonists
GLP-1 RAs in lymphedema
Patient reported quality of life outcome using LLIS
Lymphedema Life Impact Scale
Time frame: 6 months
Physiological improvement
Limb volume Bioimpedance BMI Incidence of cellulitis Compression use
Time frame: 6 months
Plan to share: Yes — De-identified study results.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: At the conclusion of the study (start date) For five years (end date)
Access criteria: All de-identified study documents will be available.
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Apr 2027, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLP-1 receptor agonists
Advanced Reconstructive Surgery Alliance